Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

NCT01750086 Phase 4 COMPLETED Results posted

The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.

Details

Lead sponsor	Massachusetts General Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	27
Start date	2013-01
Completion	2014-08

Conditions

• Postmenopausal Osteoporosis

Interventions

• Teriparatide 40-mcg subcutaneous injection
• Denosumab Injection
• Alendronate Oral Tablet

Primary outcomes

• Bone Turnover Marker (Blood Sample) — 8 weeks
  The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8.

Countries

United States